FDA grants breakthrough therapy status for Otsuka’s IgAN drug

Otsuka and Visterra reported favourable outcomes from the Phase II ENVISION clinical trial of sibeprenlimab for IgAN treatment last year. Credit: fernando zhiminaicela from Pixabay.